The President & Chief Executive Officer of Repare Therapeutics (NASDAQ: RPTX) is Selling Shares

By Carrie Williams

Today, the President & Chief Executive Officer of Repare Therapeutics (RPTXResearch Report), Lloyd Mitchell Segal, sold shares of RPTX for $193K.

In addition to Lloyd Mitchell Segal, 2 other RPTX executives reported Sell trades in the last month. Following Lloyd Mitchell Segal’s last RPTX Sell transaction on June 25, 2020, the stock climbed by 1.1%.

See today’s analyst top recommended stocks >>

Based on Repare Therapeutics’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $135K and GAAP net loss of -$15,263,000. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $8.33 million. The company has a one-year high of $46.44 and a one-year low of $21.45. Currently, Repare Therapeutics has an average volume of 53.70K.

Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $50.00, reflecting a -32.4% downside.

The insider sentiment on Repare Therapeutics has been negative according to 124 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.